# Business Request Analysis  
## Day 0 – VigilAI Pharmacovigilance Platform

**Date Received**: [Simulation – August 2025]  
**Requestor**: Head of Pharmacovigilance  
**Analyzed by**: Business Analyst / AI Product Analyst (Portfolio Simulation)

---

### 1. Original Business Request

> "We need an AI-enabled pharmacovigilance platform that can automate safety case processing, improve signal detection, reduce manual workload, and provide better visibility into drug safety operations."

---

### 2. Request Decomposition

| Stated Need | Interpretation | Business Value Driver |
|-------------|----------------|-----------------------|
| Automate safety case processing | Reduce manual effort in intake, triage, coding, narrative, quality checks | Cost, speed, consistency, scalability |
| Improve signal detection | Detect safety signals earlier and more reliably from cases + literature + other sources | Patient safety, regulatory compliance, product protection |
| Reduce manual workload | Free PV staff from repetitive tasks to focus on medical assessment and decision-making | Staff capacity, job satisfaction, quality of assessment |
| Better visibility into drug safety operations | Real-time / near real-time dashboards on case volumes, timelines, signals, compliance | Management control, inspection readiness, resource planning |

---

### 3. Current State Summary (As Described)

| Area | Current Approach | Pain Points |
|------|------------------|-----------|
| Case Intake | Safety database + manual entry from multiple sources | High volume, delayed entry, inconsistent quality |
| Case Processing | Largely manual | Time-consuming, variable quality, backlog risk |
| Literature Review | Manual screening | Labor-intensive, risk of missed relevant articles |
| Tracking | Excel trackers + emails | Version issues, limited real-time view, audit difficulty |
| Signal Detection | Traditional methods + manual review | Slower detection, resource intensive |
| Reporting & Visibility | Periodic / manual consolidation | Delayed insights for leadership |

---

### 4. Triggering Business Drivers

1. **Volume Growth** – Increasing adverse event reports
2. **Regulatory Pressure** – More stringent and global requirements
3. **Geographic Expansion** – More markets → more complexity and volume
4. **Speed Expectation** – Need for faster signal detection and case processing timelines
5. **Operational Sustainability** – Manual model does not scale efficiently

---

### 5. Initial Clarifying Questions (For Discovery)

**Strategic**
- What is the primary success metric the Head of PV cares about most in the first 12 months?
- Is the priority more on case processing efficiency or on signal detection capability (or both equally)?

**Scope**
- Which products / portfolios are in scope for Phase 1?
- Which regions / regulatory jurisdictions are priority?
- What existing safety database must we integrate with?

**Process**
- What is the current average time from case receipt to submission-ready?
- Where do the biggest bottlenecks and quality issues occur today?

**AI Appetite & Constraints**
- What level of automation is acceptable? (Full auto vs human-in-the-loop)
- Are there existing AI/ML initiatives or preferred technology partners?
- What are the compliance / validation expectations for AI components?

**Data**
- What historical case volume and data quality do we have for model training?
- How is literature currently sourced and stored?

---

### 6. Preliminary Problem Statement

The organization’s current pharmacovigilance operating model relies heavily on manual processes, fragmented tools (safety database + Excel + email), and reactive signal detection. As case volumes and regulatory complexity grow with global expansion, this model creates risks of delayed case processing, missed or late signals, staff overload, and limited real-time operational visibility. An AI-enabled platform is requested to augment human expertise, automate repetitive work, accelerate insight, and improve oversight.

---

### 7. Recommended Immediate Next Steps (Day 0 → Discovery)

1. Confirm sponsor expectations and success metrics (workshop with Head of PV)
2. Identify and map key stakeholders (PV Operations, Medical Review, Signal Management, Literature, QA/Compliance, IT, Data Science)
3. Conduct high-level AS-IS process walkthroughs for:
   - Case intake & processing
   - Literature monitoring
   - Signal detection & management
4. Assess data landscape (safety DB, literature sources, historical volumes)
5. Draft initial Project Charter and high-level scope for sponsor alignment
6. Identify quick-win AI use cases vs longer-term capabilities

---

### 8. BA / AI Product Analyst Notes

- This is a high-compliance domain → **explainability, auditability, and human oversight are non-negotiable**.
- AI should be positioned as **augmentation**, not replacement, of medical judgment.
- Strong opportunity for a compelling portfolio piece combining **Life Sciences domain + AI Product BA skills**.
